Cryptococcus neoformans is commonly associated with meningoencephalitis in immunocompromised patients and occasionally in apparently healthy individuals. Duration and regimen of antifungal treatment vary depending on the nature of the host and extent of disease and CNS shunts are placed in persistently elevated intracranial pressures. Recurrence of infection after initial treatment is not uncommon in HIV positive patients, Kaya et al. (2012) and Illnait-zaragozí et al. (2010). We describe a 39-year-old immunocompetent female that presented with neurologic deficits and increased intracranial pressure (ICP) due to cryptococcal meningoencephalitis that had a complicated course with drug induced hepatitis and persistently increased ICP that ultimately required shunt placement and presented again with relapse of cryptococcal meningoencephalitis after completion of antifungal treatment. Our case shows that recurrent cryptococcal meningitis can be seen in immunocompetent patients due to prolonged placement of CNS shunt and suggests that shunts should be removed after resolution of meningitis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171049 | PMC |
http://dx.doi.org/10.1155/2014/407348 | DOI Listing |
Clin Nucl Med
February 2025
From the Department of Radiology, Tokushima University Hospital, Tokushima, Japan.
A 70-year-old man experienced an epileptic seizure. Subsequent MRI performed on close examination revealed high signal in the left occipital cortex on fluid-attenuated inversion recovery. Gadolinium contrast indicated enhancement along the cortex.
View Article and Find Full Text PDFJ Mycol Med
December 2024
Fimlab Laboratories, 33520 Tampere, Finland / Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland; Northern Finland Laboratory Centre (NordLab), 90220 Oulu / Finland and Research Unit of Biomedicine, University of Oulu, 90570 Oulu, Finland.
Background: Cryptococcus neoformans is an important fungal pathogen causing pneumonia and central nervous system infections mainly in immunocompromised hosts. Fingolimod is an immunomodulatory drug approved in the US and Europe for the treatment of multiple sclerosis.
Case Presentation: We herein report a case of cryptococcal meningoencephalitis in a 46-year-old male with a history of fingolimod for five years.
Curr Med Mycol
April 2024
Department of Biotechnology, College of Science, University of Anbar, Ramadi, Anbar, Iraq.
Background And Purpose: and are highly virulent species that cause diseases, such as meningoencephalitis and pulmonary infections. The gene predominantly determines the virulence of the pathogenic species. This study aimed to examine in both pathogenic and non-pathogenic species.
View Article and Find Full Text PDFFront Immunol
December 2024
Department of Neurology Medicine, The Second Hospital of Shandong University, Cheeloo College of Medicine of Shandong University, Shandong University, Jinan, China.
We report on a previously non-HIV-diagnosed, 47-year-old male diagnosed with diabetes mellitus (DM) and cryptococcal meningoencephalitis, who was referred to our institution for antifungal treatment. During the course of treatment, due to the development of refractory intracranial hypertension, Ommaya reservoirs were employed for cranial pressure reduction. The patient gradually recovered during subsequent antifungal therapy; however, symptoms worsened in the third month of treatment, leading to consideration of post-infectious inflammatory response syndrome (PIIRS) on examination.
View Article and Find Full Text PDFmBio
December 2024
Department of Plant Biology, University of Georgia, Athens, Georgia, USA.
Unlabelled: Cryptococcal meningoencephalitis (CME) is deadly. CME is responsible for 19% of deaths in AIDS patients, and its global mortality is greater than 60%. The recommended CME therapy requires amphotericin B (AmB), a fungicidal drug targeting fungal ergosterol.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!